What is the share price of Bacil Pharma Ltd (BACPHAR) today?
The share price of BACPHAR as on 30th June 2025 is ₹35.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Bacil Pharma Ltd (BACPHAR) share?
The past returns of Bacil Pharma Ltd (BACPHAR) share are- Past 1 week: N/A%
- Past 1 month: -13.84%
- Past 3 months: -19.55%
- Past 6 months: -35.43%
- Past 1 year: 65.13%
- Past 3 years: 481.17%
- Past 5 years: 1303.92%
What are the peers or stocks similar to Bacil Pharma Ltd (BACPHAR)?
The peers or stocks similar to Bacil Pharma Ltd (BACPHAR) include:What is the market cap of Bacil Pharma Ltd (BACPHAR) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bacil Pharma Ltd (BACPHAR) is ₹21.09 Cr as of 30th June 2025.What is the 52 week high and low of Bacil Pharma Ltd (BACPHAR) share?
The 52-week high of Bacil Pharma Ltd (BACPHAR) is ₹62.56 and the 52-week low is ₹14.85.What is the PE and PB ratio of Bacil Pharma Ltd (BACPHAR) stock?
The P/E (price-to-earnings) ratio of Bacil Pharma Ltd (BACPHAR) is 51.43. The P/B (price-to-book) ratio is 17.28.Which sector does Bacil Pharma Ltd (BACPHAR) belong to?
Bacil Pharma Ltd (BACPHAR) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Bacil Pharma Ltd (BACPHAR) shares?
You can directly buy Bacil Pharma Ltd (BACPHAR) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Bacil Pharma Ltd
BACPHAR Share Price
35.804.99% (-1.88)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
BACPHAR Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
BACPHAR Performance & Key Metrics
BACPHAR Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 50.21 | 17.28 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.15 | 6.59 | 0.81% |
BACPHAR Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BACPHAR Company Profile
Bacil Pharma is engaged in the business of manufacturing of pharmaceuticals, medicinal chemicals and botanical products.
SUNPHARMA
PE Ratio
36.80
36.80
1Y Return
7.60%
7.60%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.18
23.18
1Y Return
2.20%
2.20%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
59.65
59.65
1Y Return
17.34%
17.34%
Buy Reco %
70.83
70.83
DRREDDY
PE Ratio
19.24
19.24
1Y Return
0.89%
0.89%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
22.26
22.26
1Y Return
11.97%
11.97%
Buy Reco %
44.44
44.44
BACPHAR Forecast
BACPHAR Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BACPHAR
BACPHAR
Income
Balance Sheet
Cash Flow
Annual Normal View
BACPHAR Income Statement
BACPHAR Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.17 | 0.27 | 0.09 | 0.14 | 0.07 | 0.06 | 0.11 | 0.13 | 0.66 | 0.66 | ||||||||||
Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.24 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||
| Employee Cost | 0.08 | 0.13 | 0.08 | 0.09 | 0.05 | 0.06 | 0.09 | 0.10 | ||||||||||||
| Selling & Administrative Expenses | 0.08 | 0.13 | 0.16 | 0.08 | 0.08 | 0.09 | 0.08 | 0.08 | ||||||||||||
| Operating & Other expenses | 0.01 | 3.73 | 0.18 | 0.27 | 0.17 | 3.76 | 0.04 | 0.01 | ||||||||||||
EBITDA | 0.00 | -3.72 | -0.34 | -0.30 | -0.23 | -3.85 | -0.10 | -0.06 | 0.41 | 0.42 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBIT | 0.00 | -3.73 | -0.35 | -0.31 | -0.23 | -3.85 | -0.10 | -0.06 | 0.41 | 0.42 | ||||||||||
| Interest & Other Items | 0.00 | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBT | 0.00 | -3.76 | -0.35 | -0.32 | -0.23 | -3.85 | -0.10 | -0.06 | 0.41 | 0.42 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| Net Income | 0.00 | -3.76 | -0.35 | -0.32 | -0.23 | -3.85 | -0.10 | -0.06 | 0.41 | 0.42 | ||||||||||
| EPS | 0.00 | -6.38 | -0.59 | -0.54 | -0.39 | -6.54 | -0.17 | -0.10 | 0.69 | 0.71 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
BACPHAR Company Updates
BACPHAR Stock Peers
BACPHAR Past Performance & Peer Comparison
BACPHAR Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bacil Pharma Ltd | 51.43 | 17.28 | — |
| Sun Pharmaceutical Industries Ltd | 36.80 | 5.99 | 0.95% |
| Cipla Ltd | 23.18 | 3.91 | 1.06% |
| Torrent Pharmaceuticals Ltd | 59.65 | 16.63 | 0.95% |
BACPHAR Stock Price Comparison
Compare BACPHAR with any stock or ETFCompare BACPHAR with any stock or ETF
BACPHAR
BACPHAR Holdings
BACPHAR Shareholdings
BACPHAR Promoter Holdings Trend
BACPHAR Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 20.51%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BACPHAR Institutional Holdings Trend
BACPHAR Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BACPHAR Shareholding Pattern
BACPHAR Shareholding Pattern
BACPHAR Shareholding History
BACPHAR Shareholding History
Mutual Funds
smallcases containing BACPHAR stock
smallcases containing BACPHAR stock
Looks like this stock is not in any smallcase yet.
BACPHAR Events
BACPHAR Events
BACPHAR Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BACPHAR has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BACPHAR Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BACPHAR has not given any dividends in last 5 years
BACPHAR Dividends
BACPHAR Dividends
Hmm, looks like data is unavailable here. Please come back after some timeBACPHAR Stock News & Opinions
BACPHAR Stock News & Opinions
Articles & Videos
Earnings
Bacil Pharma reports standalone net profit of Rs 0.02 crore in the March 2025 quarter
Net profit of Bacil Pharma reported to Rs 0.02 crore in the quarter ended March 2025 as against net loss of Rs 0.04 crore during the previous quarter ended March 2024. There were no Sales reported in the quarter ended March 2025 and during the previous quarter ended March 2024. For the full year,net profit reported to Rs 0.40 crore in the year ended March 2025 as against net loss of Rs 0.06 crore during the previous year ended March 2024. There were no Sales reported in the year ended March 2025 and during the previous year ended March 2024.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Bacil Pharma to table results
Bacil Pharma will hold a meeting of the Board of Directors of the Company on 26 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Bacil Pharma reports standalone net loss of Rs 0.06 crore in the December 2024 quarter
Net Loss of Bacil Pharma reported to Rs 0.06 crore in the quarter ended December 2024 as against net loss of Rs 0.02 crore during the previous quarter ended December 2023. There were no Sales reported in the quarter ended December 2024 and during the previous quarter ended December 2023.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Bacil Pharma to discuss results
Bacil Pharma will hold a meeting of the Board of Directors of the Company on 21 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Bacil Pharma to convene EGM
Bacil Pharma announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 14 November 2024 .Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Bacil Pharma reports standalone net profit of Rs 0.48 crore in the September 2024 quarter
Net profit of Bacil Pharma reported to Rs 0.48 crore in the quarter ended September 2024 as against net loss of Rs 0.01 crore during the previous quarter ended September 2023. There were no Sales reported in the quarter ended September 2024 and during the previous quarter ended September 2023.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Bacil Pharma to convene board meeting
Bacil Pharma will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Bacil Pharma schedules board meeting
Bacil Pharma will hold a meeting of the Board of Directors of the Company on 15 October 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Bacil Pharma announces board meeting date
Bacil Pharma will hold a meeting of the Board of Directors of the Company on 27 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Bacil Pharma to conduct AGM
Bacil Pharma announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 36.36%, vs industry avg of 10.14%
Over the last 5 years, market share stayed at 0%